The goal of this clinical trial is to discover the prevalence of NHPH bacteria (Non-Helicobacter pylori Helicobacter species) in patients with one of the following conditions: 1. Functional dyspepsia following the Rome IV criteria 2. Active chronic gastritis, non-H. pylori induced atrophic gastritis, intestinal metaplasia and non-H.pylori gastric dysplasia 3. Gastric cancer, including siewert type 2 and 3 esophagastric junction cancers In addition, patients undergoing bariatric surgery are included as a control group. This study will be conducted using a prospective analysis in the three targeted study populations. Biopsy specimens routinely taken during the medical procedure or via the resected material in patients belonging to the target groups will be used. Exclusion criteria: * Patients with a history of H. pylori infection diagnosed by serology, on gastric biopsy, by breath test or on antigen test in stool samples. * Pregnancy. * Underage patients (\< 18 years).
Study Type
OBSERVATIONAL
Enrollment
150
UZA
Edegem, Belgium
RECRUITINGAZ Maria Middelares
Ghent, Belgium
RECRUITINGAZ Groeninge
Kortrijk, Belgium
RECRUITINGWhat is the prevalence of NHPH in patients with (pre)malignant gastric lesions
Time frame: During the 1st (and only visit)
Impact of NHPH infection on the mucin gene expression
What is the impact of NHPH presence on the mucin gene expression in the gastric antrum and corpus in the three abovementioned patient groups? Therefore, differential expression of mRNA (isoform) expression of a mucin gene set will be performed by targeted long-read and bulk short-read sequencing allowing to identify all mucins that are expressed in the three target groups.
Time frame: During the 1st (and only visit)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.